VRAX Virax Biolabs Group Limited: ערך חשבונאי למניה

Following the pandemic, Virax Biolabs Group (VRAX) faced an oversupply and a forced sell-off of inventories. The calculated book value per share on this chart illustrates capital dynamics, where 13.07 determines the current status of the parameter. Meanwhile, the business relies on AI-driven immunity analysis for precise diagnostics and is implementing mobile early detection systems for global biological threats.

Virax Biolabs Group's expansion into the mobile diagnostic platforms segment drives net asset value growth by expanding its material base. This metric reflects the liquidation value per share, calculated as the difference between all assets and liabilities, which allows the book value per common share to assess the business's real foundation and capital accumulation efficiency without market noise.